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Background: A body of empirical work demonstrates that wide fluctuations in a person’s blood pressure across
consecutive measures, known as blood pressure variability (BPV), hold prognostic value to predict stroke and transient
ischemic attack. However, the magnitude of association between BPV and other neurological outcomes remains less
clear. This systematic review aims to pool together data regarding BPV with respect to incident dementia, cognitive
impairment, and cognitive function.
Methods: Electronic databases (MEDLINE, EMBASE, and SCOPUS) will be searched for the key words blood pressure
variability and outcomes of dementia, cognitive impairment, and cognitive function. Authors and reference lists of
included studies will also be contacted to identify additional published and unpublished studies. Eligibility criteria are
as follows: population—adult humans (over 18 years but with no upper age limit) without dementia at baseline, with
or without elevated blood pressure, or from hypertensive populations (systolic blood pressure ≥ 140 mmHg and/or
diastolic blood pressure ≥ 90 mmHg or use of antihypertensive drug for hypertension) and from primary care,
community cohort, electronic database registry, or randomized controlled trial (RCT); exposure—any metric of
BPV (systolic, diastolic or both) over any duration; comparison—persons without dementia who do not have
elevated BPV; and outcome—dementia, cognitive impairment, cognitive function at follow-up from standardized
neurological assessment, or cognitive testing. Article screening will be undertaken by two independent reviewers
with disagreements resolved through discussion. Data extraction will include original data specified as hazard ratios,
odds ratios, correlations, regression coefficients, and original cell data if available. Risk of bias assessment will be
undertaken by two independent reviewers. Meta-analytic methods will be used to synthesize the data collected
relating to the neurological outcomes with Comprehensive Meta-Analysis Version 2.0 (Biostat Inc., Engelwood, NJ).
Discussion: This systematic review aims to clarify whether BPV is associated with elevated risk for dementia, cognitive
impairment, and cognitive function. An evaluation of the etiological links between BPV with incident dementia might
inform evidence-based clinical practice and policy concerning blood pressure measurement and hypertension
management. The review will identify sources of heterogeneity and may inform decisions on whether it is feasible and
desirable to proceed with an individual participant data meta-analysis.
Systematic review registration: PROSPERO CRD42017081977
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Background
Dementia is a highly debilitating disease, leading to pro-
found impairments in quality of life, and comes at great
individual, familial, societal, and economic cost. Hyperten-
sion, especially in mid-life, is a leading modifiable risk fac-
tor for dementia and cognitive decline [1, 2]. The majority
of dementia cases have a mix of neurodegenerative and
vascular-type pathology evident upon autopsy and brain
imaging (e.g., β-amyloid in the former, lacunes in the lat-
ter) [3, 4]. The potential for antihypertensive drugs to re-
duce vascular lesion burden in the brain and dementia
risk is a common hypothesis. To date, some randomized
controlled trials (RCTs) indicate that differences between
active treatment and placebo in systolic blood pressure re-
duction are associated with cognitive outcome [5–7].
However, the evidence has not favored one particular anti-
hypertensive drug class over others [8–10], and there is no
clear hypertension management guideline to assist clini-
cians hoping to mitigate dementia or cognitive impair-
ment [1]. Clearly, there is more to understand about the
role of blood pressure in dementia risk.
A line of research in neurology and cardiology suggests
that the intra-individual variability across successive blood
pressure readings may be important to neurological
outcomes of incident and recurrent stroke or transient is-
chemic attack [11–14]. However, the magnitude of associ-
ation between such blood pressure fluctuation, known as
blood pressure variability (BPV), and other neurological
outcomes remains less clear [15–17]. Though incom-
pletely understood, high BPV potentially leads to carotid
artery denervation and endothelial damage reducing per-
fusion in microvascular vessels [18]. In support of BPV’s
relevance to brain health, magnetic resonance imaging
studies indicate that BPV in mid-life is associated with
greater white matter hyperintensity (WMH) burden [17],
with WMH a strong predictor of dementia and stroke
[19]. Likewise, higher ambulatory BPV is associated with
enlarged perivascular spaces in the brain [20], microin-
farcts, and cerebral microbleeds [21]. Moreover, associa-
tions between BPV and hippocampal volumes have been
shown in cross-sectional analysis [21], and atrophy in this
brain region of interest possibly explains other clinical
observations from high BPV such as cognitive dysfunc-
tion [21–23] or decline [24], dementia [25–27], and
late-onset depression [28, 29]. Collectively, there is evi-
dence to suggest that BPV may contribute to vascular
pathologies in the brain as well as risk for dementia
and cognitive impairment.
Prior systematic reviews concerning blood pressure and
dementia have predominantly focused on hypertension or
antihypertensive drugs [8, 9, 30–37]. Meta-analyses of
BPV have been reported for the neurological outcomes of
acute stroke and transient ischemic attack [12] and
head-ache [38]. Otherwise, only narrative reviews were
reported for the potential role of BPV in dementia and
cognitive dysfunction [39–42]. Given the reduction in
treat-to-target blood pressure level in recent guidelines
[43], and uncertainty around the optimal blood pressure
for brain health [1], it is imperative to clarify the role of
blood pressure and its variability in relation to demen-
tia [44]. A systematic review and meta-analysis pertain-
ing to BPVs’ association with dementia, cognitive
impairment, and cognitive function might in turn assist




The proposed review aims to synthesize the evidence base
regarding BPV and subsequent dementia or cognitive im-
pairment. The reporting of this protocol conforms to the
PRISMA-P guidelines [45] (shown in Additional file 1)
and was registered on the PROPSERO database
[CRD42017081977] on the 8th of December, 2017 [46].
The full review will conform to the PRISMA guidelines
[47]. PJT is guarantor of this review. Updates to this re-
view will be registered on PROSPERO.
Search strategy
We will identify relevant articles in any language by
searching electronic databases from inception including
the following: MEDLINE, EMBASE, and SCOPUS. The
MEDLINE search strategy is provided in Additional file 2.
We will perform a hand search of the reference lists of
articles selected to supplement the electronic search.
The principal investigators of studies will also be con-
tacted to ascertain unpublished data and determine
other studies not yielded by our primary search. The
grey literature/unpublished studies will not be searched
on an electronic database.
Eligibility criteria
Population: the population of interest are adult humans
(over 18 years but with no upper age limit) from the
general population, primary care, or other population,
without verified or known dementia at baseline, whom
underwent consecutive blood pressure measures. Per-
sons may be with or without elevated blood pressure or
from hypertensive populations (systolic blood pressure
≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg
or use of antihypertensive drug for hypertension). To be
eligible, blood pressure must be quantified by a valid
method standardized within studies including office,
home, ambulatory, or beat-to-beat measures from which
BPV was calculated, or can be determined by published
results or clarified by authors. In the case that studies in-
clude persons with dementia at baseline, we specify that
the association between BPV and incident dementia
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must be reported separately to be included in the sys-
tematic review analyses.
Exposure: any measure of BPV (systolic, diastolic, or
both) calculated utilizing any common metric (e.g., stand-
ard deviation [SD], average real variability [ARV], coeffi-
cient of variation [CV]) for systolic and diastolic BPV [48].
BPV data will be extracted and prioritized in the order of
beat-to-beat, 24-h ambulatory blood pressure monitoring
(ABPM), awake ABPM measures (versus sleep), office/
clinic/casual (also known as visit-to-visit), and home blood
pressure monitoring. Instances where the BPV M± SD
data are reported for more than two groups, data will be
extracted for the highest BPV versus lowest BPV group
(in tertiles, quartiles, quintiles, or deciles) to ensure
that only one effect size is analyzed per study and that
dissimilar n = k groups are pooled in analyses.
Comparator/control: participants without verified or
known dementia, and without elevated BPV at baseline
from the general population, primary care, or other popu-
lation. There are no known normative values for elevated
and non-elevated BPV, which will likely be reported ac-
cording to within study cutoffs (e.g., in tertiles, quartiles,
quintiles, or deciles).
Outcomes:
1. Dementia—defined as a diagnosis according to
a recognized and standardized clinical criteria
(e.g., National Institute of Neurological and
Communicative Disorders and Stroke and Alzheimer’s
Disease and Related Disorders Association
[NINCDS-ADRDA], National Institute of
Neurological Disorders and Stroke Association-
Internationale pour la Recherche en
l’Enseignement en Neurosciences [NINDS-AIREN],
Diagnostic and Statistical Manual of Mental
Disorders [DSM]) or a diagnosis made by a qualified
professional (e.g., neurologist, geriatrician,
psychiatrist, general physician). Dementia will be
considered in any of the following categories:
Alzheimer’s disease (AD), vascular dementia
(VaD), mixed dementia, dementia unspecified,
and other dementia. In studies reporting multiple
dementia subtypes, we will initially extract total
incident dementia for primary analyses and
evaluate subtypes in stratified analyses. When
levels of AD diagnoses were provided within the
same study, we will prioritize probable AD and
exclude possible AD.
2. Cognitive impairment or decline—defined as an
objective cognitive impairment or between assessment
decline (e.g., 1 SD reduction, reliable change index)
or below age-sex appropriate normative data on a
standardized test of cognitive function representing
memory (episodic memory, semantic memory, or
overall memory ability), language (verbal fluency),
speed (processing speed), visuospatial abilities,
or executive functioning (working memory,
reasoning, attention, or overall executive
functioning) or global cognition, including the
Mini Mental State Examination [49]. Self-reported
cognitive decline will not be considered.
3. Cognitive function—defined as cognitive test scores
on a standardized test of cognitive function
representing memory (episodic memory, semantic
memory or overall memory ability), language
(verbal fluency), speed (processing speed),
visuospatial abilities, or executive functioning
(working memory, reasoning, attention, or overall
executive functioning) or global cognition,
including the Mini Mental State Examination [49].
Self-reported cognitive function will not be considered.
We will assess the primary outcomes as independent
outcomes: incident dementia (level 1), cognitive impair-
ment or decline (level 2), cognitive function (level 3), and
any dementia or cognitive impairment or decline (com-
bining study data for level 1 and level 2 outcomes).
Study design
Only peer reviewed studies in full-text, conference ab-
stract or doctoral dissertations are eligible for this review
if published in English [50]. Observational studies de-
signed as longitudinal cohort, case–control study, or data-
base registry and experimental studies designed as RCTs
or non-randomized trials will be eligible. Prospective and
retrospective studies will also be eligible. We will exclude
cross-sectional studies, case series, and case reports.
Exclusion
Studies utilizing only patient self-report to determine
incident dementia or cognitive impairment, including
self-report of a physician’s diagnosis that is not further
verified consistent with the definitions listed under study
outcomes (levels 1–3), are excluded. Studies reporting de-
mentia secondary to a primary degenerative or neurological
condition or insult are excluded (e.g., tumor, infection, trau-
matic brain injury, Wernicke’s encephalopathy).
Study selection process
Initially, two reviewers will independently screen titles
and abstracts of all the retrieved bibliographic records.
Full texts of all potentially eligible records passing the
title and abstract screening level will be retrieved and
examined independently by the two reviewers according
to the abovementioned eligibility criteria. Disagreements
at both screening levels (title/abstract and full text) will
be adjudicated by discussion with a third reviewer. A
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PRISMA flow chart will outline the study selection
process and reasons for exclusions.
Data items for collection
After determination of the initial study, eligibility informa-
tion will be extracted for each study pertaining to study
identification (first author, year of publication, country
where recruitment took place), study design and charac-
teristics (sample size, duration of follow-up, attrition),
characteristics of the population under study (age, sex,
education, systolic and diastolic blood pressure, propor-
tion with hypertension, hypercholesterolemia, diabetes,
kidney disease, liver disease, stroke, apolipoprotein ε4
polymorphism, coronary heart disease, and heart failure),
BPV exposure (methodology or methodologies), dementia
adjudication (criteria, subtypes, use of consensus panel,
number of endpoints), cognitive testing (full list of cogni-
tive test(s) and their domains), effect size (unadjusted and
most adjusted effect size or raw numbers), adjustment for
covariates (list of variables), and funding (grant numbers
or acknowledgement). Primary outcome data collected
will include the type of cognitive outcome, reported either
as categorical numbers (numerator and denominator), or
the statistical effect size (e.g., risk ratio, hazard ratio) and
the 95% confidence interval (CI). These variables will be
extracted for all studies by one reviewer, after which the
extracted data will be verified by a second reviewer to re-
duce reviewer errors and bias. All disagreements will be
handled by consensus between the two reviewers. Data
will be managed at the coordinating center (University of
Adelaide).
Risk of bias
The RTI item bank will be utilized to identify methodo-
logical bias among the identified studies at the
study-level [51]. The RTI item bank consists of 29 items
for evaluating the risk of bias in observational studies,
interventions, or exposures. The RTI was developed
from an initial pool of 1492 items based on face validity,
cognitive, content validity, and interrater reliability test-
ing. The scale has demonstrated interrater reliability.
Risk of bias will be independently undertaken by two re-
viewers, and disagreements resolved by consensus. The
RTI item bank is provided in Additional file 3.
Synthesis of data and summary measures
Data synthesis
We will provide a detailed description of the results in
both tables and text for all included studies. We will quali-
tatively describe the studies pertaining to study identifica-
tion (first author, year of publication, country where
recruitment took place), study design and characteristics
(observational or experimental, sample size, duration of
follow-up), patient population (age, sex), the methods
used to quantify BPV, the type of cognitive endpoint
(dementia, cognitive impairment, cognitive function), and
adjustment for covariates (list of variables).
Meta-analysis
We will use Comprehensive Meta-Analysis Version 2.0
(Biostat Inc., Engelwood, NJ) to conduct the
meta-analyses. The summary effect measures may include
d family effect sizes (e.g., hazard ratios, relative risk, odds
ratios, Cohen’s d) or r family effect sizes (e.g., r, β). When
data are available to be pooled together, we will use a
random-effects model using the inverse variance method
which provides a more conservative estimate of effect size.
Where possible, we will aggregate each included study’s
cognitive outcome data from the d family of effect sizes
with the associated 95% CIs. Hazard ratios, relative risk,
and odds ratios are presumed to measure the same under-
lying effect [52] and consensus that these are approxi-
mately equivalent for effect sizes less than 2.5 and
follow-up less than 20 years [53]. In studies where an ef-
fect size is not reported, we will extract the individual cell
data and calculate the RR and 95% CI where possible.
The r family effect sizes will be converted to the com-
mon metric r and pooled together with their associated
95% CI.
In the first instance, we will pool together the un-
adjusted effect sizes for each cognitive outcome (permit-
ting age and sex adjustment). In the second instance, we
will pool together the most adjusted effect sizes for each
cognitive outcome. Heterogeneity will be evaluated with
two measures of between-study heterogeneity: the I2 stat-
istic and tau (equivalent to SD of pooled r). According to
the Cochrane Handbook for Systematic Reviews [54], I2 of
0–60% can be regarded as not important to moderate
(0–60%), while I2 > 60% indicates substantial heterogeneity.
Planned subgroup analyses
Subgroup analyses will be performed for the combined
cognitive outcome (combination of level 1 dementia and
level 2 cognitive impairment or decline data) stratified
by sex if possible. In the event that stratified sex analyses
is not possible, we will utilize meta-regression to per-
form analyses adjusted for the percentage of males/fe-
males in the total sample, and age (mean or median).
Sensitivity analyses will evaluate the effects of age < 50
and > 50 years, or alternatively as mean or median age
in meta-regression. This is based on the a priori higher
probability for older persons to have dementia and the
age-dependent relationship between mid-life blood pres-
sure and dementia [55]. Also, a subgroup analysis will be
performed, if possible, stratifying by dementia sub-types
of Alzheimer’s disease and vascular dementia.
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Planned sensitivity analyses
Sensitivity analyses will be performed for the primary cog-
nitive endpoint (combination of level 1 dementia and level
2 cognitive impairment or decline data). The period dur-
ing which blood pressure was measured may be a source
of methodological heterogeneity. We will therefore stratify
analyses according to blood pressure measurement inter-
vals as: 24 h or less (e.g., beat-to-beat, 24-h ABPM), short
term > 24 h to 1 month, medium term > 1 month to ≤
12 months, and long term > 12 months. We will also as-
sess general study-level characteristics as potential sources
of heterogeneity (1) studies adjusting for reverse causation
bias by excluding dementia events occurring in the years
of follow-up when BPV was calculated, (2) global region
of recruitment, (3) unpublished studies, and (4) length of
follow-up. Due to the insidious prodromal phase of de-
mentia, we will also perform a meta-regression based on
attrition and mean follow-up time to consider competing
risks and survivor bias [56]. Follow-up duration will be di-
chotomized as short term (up to 5 years) and medium to
long term (more than 5 years). This was based on the con-
sensus that exposure to antihypertensive drugs in RCTs
have likely been too short (< 5 years) for antihypertensive
treatment to positively impact on cognition [57]. We in-
tend to group all studies together initially and then
perform sensitivity analyses for different time points
(e.g., dementia in the short and long term), if possible.
Assessment of publication bias
The test of Egger et al. [58] and the funnel plot will be
used to evaluate the presence of publication bias.
GRADE framework for quality of evidence
The proposed review will use the Grading of Recommen-
dations Assessment, Development and Evaluation
(GRADE) guidelines [59] to determine the quality of evi-
dence and the strength of recommendations. The GRADE
guidelines will be applied separately to each of the cogni-
tive endpoints, providing a summary of findings tables
with qualitative description as either high, moderate, low,
or very low.
Discussion
This systematic review aims to add to the literature by ag-
gregating data concerning the risk of dementia and cogni-
tive impairment attributable to BPV. Our review will
contribute to the literature by clarifying whether BPV, de-
rived from consecutive blood pressure measurements, is
associated with these cognitive outcomes. It is well estab-
lished that hypertension in mid-life is associated with an
increased risk for dementia [55]. However, RCTs of anti-
hypertensive drugs have not consistently reduced demen-
tia risk. The findings of our review might therefore serve
to clarify the design of future epidemiological and clinical
studies. The findings might also potentially inform
evidence-based clinical practice and policy regarding
blood pressure measurement and hypertension manage-
ment, especially in older persons at greater risk for cogni-
tive impairment and conversion to dementia.
There are several limitations that will contextualize the
findings and generalizability of the proposed review in-
cluding that high BPV (e.g., upper quintile of the popula-
tion) is the result of complex interactions between
cardiovascular regulatory mechanisms (neural central,
neural reflex) and environmental and behavioral factors
[18]. As such, we may not be able to identify antecedent
risk factors for higher BPV or ways to modulate BPV in
order to lessen dementia risk. Similarly, BPV can be
dependent on mean blood pressure in some methodolo-
gies (e.g., coefficient of variation); thus, it may be difficult
to extrapolate the effects of BPV independent from mean
blood pressure. The included studies will also potentially
measure blood pressure at different intervals ranging from
beat-to-beat to long-term visit-to-visit in epidemiological
studies, which could introduce methodological heterogen-
eity. Limitations will also relate to the adjudication of de-
mentia outcomes with varying levels of validity and
heterogeneity. The ability for correct adjudication of de-
mentia outcomes will be invariably related to the age of
participants and the length of follow-up. This limitation is
important in our proposed review’s context since we are
largely assessing etiological links between BPV and de-
mentia. Limitations of the original studies may also in-
clude between study heterogeneity and high risk of bias
that will potentially limit the conclusions drawn. The pro-
posed systematic review is likely to be limited by publica-
tion bias of only significant findings, given the relatively
recent interest in BPV since Rothwell and colleagues sem-
inal work on this topic [11–13]. Moreover, as the pro-
posed review will include only English language studies,
the generalizability of the findings to studies published in
other languages and other healthcare settings is limited.
In conclusion, given that there is still uncertainty around
the optimal blood pressure for brain health [1], it is im-
perative to clarify the role of BPV on cognitive outcomes.
The proposed review will help in summarizing the avail-
able evidence, and the findings may have implications for
clinical practice and policy concerning blood pressure
measurement and hypertension management. The review
will identify sources of heterogeneity and may inform de-
cisions on whether it is feasible and desirable to proceed
with an individual participant data meta-analysis.
Additional files
Additional file 1: PRISMA-P checklist of reporting items for this systematic
review protocol. This file shows the page number for each item on the
PRISMA-P checklist. (PDF 372 kb)
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Additional file 2: Table showing the search strings for MEDLINE. This
table shows the search string for the systematic review for the MEDLINE
database utilized in this review. This search string will be adapted for
EMBASE and SCOPUS. (PDF 440 kb)
Additional file 3: RTI risk of bias item bank. This table shows each of
the items of the RTI item bank used in our study. Each of the studies
selected for full-text review will be scored to these items by two re-
viewers. (PDF 454 kb)
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